Vol 10, Supplement 9 (April 24, 2018): Journal of Thoracic Disease

Editorial

Individualized clopidogrel suspension strategy coronary artery bypass surgery: what is the best choice?
Rafik Margaryan, Michele Murzi
Atlas is not alone: sharing the burden of clinical challenge
Alejandro Bribriesco, Siva Raja, Usman Ahmad
Editorial on “enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, openlabel, parallel-group study (NUTRIREA-2)”
Pierre Singer, Sornwichate Rattanachaiwong
Endovascular treatment for chronic type B aortic dissection: current opinions
Luigi Di Tommaso, Raffaele Giordano, Ettorino Di Tommaso, Gabriele Iannelli
Improving postoperative pain management after video-assisted thoracic surgery lung resection contributes to enhanced recovery, but guidelines are still lacking
Marco Mercieri, Antonio D’Andrilli, Roberto Arcioni
Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design
Taylor R. Cushman, Vivek Verma, Jean-Claude M. Rwigema
Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
Jaseela Chiramel, Rebecca Tay, Raffaele Califano
Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer
Habeeb Majeed, Eitan Amir
The intrepid adventure of early transcatheter mitral valve replacement
Qasim Stanazai, Mohamad Alkhouli
Biomarkers in malignant pleural mesothelioma: current status and future directions
Tamkin Ahmadzada, Glen Reid, Steven Kao
Early experience with transcatheter mitral valve replacement: successes, challenges, and future directions
Chetan P. Huded, Milind Y. Desai
The renaissance of photodynamic therapy for early esophageal cancer: is it the time?
Alfonso Fiorelli, Aldo Prencipe, Mario Santini
Demise of lung transplants: exposing critical gaps in understanding lung stem cells
Wa Xian, Frank McKeon
Prone positioning in acute respiratory distress syndrome: why aren’t we using it more?
Mark L. Hepokoski, Mazen Odish, Atul Malhotra
Primary small cell cancer of the esophagus: understanding treatment outcomes
Tara R. Semenkovich, Bryan F. Meyers
VATS lobectomy: does surgical heterogeneity prevent evidence on pain control?
Luigi Santambrogio, Valeria Musso
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
Pascale Tomasini, Laurent Greillier, Arnaud Boyer, Arnaud Jeanson, Fabrice Barlesi
Surgery for limited-stage primary small cell carcinoma of the esophagus: is it feasible and for whom is it indicated?
Hirotoshi Kikuchi, Hiroya Takeuchi
Intrepid steps towards clinical prime time
Rodrigo Mendirichaga, Vikas Singh
The management of malignant pleural mesothelioma in the USA 2004-13—a decade of lost opportunity?
David A. Waller
Improving the care for elective surgical patients: post-operative ICU admission and outcome
Salvatore Lucio Cutuli, Simone Carelli, Gennaro De Pascale, Massimo Antonelli
Analgesic management after thoracoscopic surgery: recent studies and our experience
Hiroaki Kuroda, Yukinori Sakao
From low-dose to no-dose: thin-section magnetic resonance imaging for evaluation of pulmonary nodules
Tommaso D’Angelo, Thomas J. Vogl, Julian L. Wichmann
APRV for ARDS: the complexities of a mode and how it affects even the best trials
Eduardo Mireles-Cabodevila, Siddharth Dugar, Robert L. Chatburn
Similar results of robotic and uniportal videothoracoscopic surgery for lung cancer treatment
Giulia Veronesi, Stefanos Bonovas
New classification—new problems to solve
Marcin Zieliński, Robert Kwiatkowski
Steroids for sepsis: yes, no or maybe
Paul E. Marik
Unraveling the etiology of primary malignant melanoma of the esophagus
Michael Krauthammer
Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
Francesco Passiglia, Luis E. Raez, Christian Rolfo
Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy
Srishti Saha, Sahil Khanna
Biomarkers in malignant mesothelioma—an unfulfilled need or a waste of resources?
Robin Cornelissen, Joachim G.J.V. Aerts
Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: old wine in a new bottle
Xiaoyun He, Qijia Yan, Gaoyan Kuang, Yixuan Wang, Pengfei Cao, Chunlin Ou
Improved lymph node staging in early-stage lung cancer in the national cancer database: commentary
Hisashi Saji, Koji Kojima, Haruhiko Nakamura
Tri-modality treatment in N2 stage IIIa non-small cell lung cancer: proper sequence remains unknown
Ze-Rui Zhao, Calvin S.H. Ng
Obstructive sleep apnea and stroke: hand in hand?
Owen D. Lyons, Clodagh M. Ryan
Sleep-disordered breathing in the elderly: is it distinct from that in the younger or middle-aged populations?
Hiroki Kitakata, Takashi Kohno, Keiichi Fukuda
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study
Takehiro Uemura, Toyoaki Hida
GGO and minimally invasive adenocarcinomas: how to deal with?
Nicolas Girard
Prognostic factors of patients with pathologic stage I lung adenocarcinoma
Ying-Yi Chen, Tsai-Wang Huang
Does immunosuppression affect the course of septic shock?
Gulbin Aygencel

Disclosure:

The supplement was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding.